What Investors Look For in the Aesthetic Sector
Share This Episode
EPISODE 009
Aesthetics represents a major financial opportunity for many investors and our panelist are taking full advantage of it. This month’s podcast features a panel discussion from the top people and firms who have a track record of successful investments in aesthetics recorded live during this year’s Aesthetics Innovation Summit.
There is no better group of investors to hear about investing and raising capital than this group! The panelist includes Craig Drill, President of Craig Drill Capital; Adele C. Oliva, Founding Partner at 1315 Capital; Irina Erenburg, CEO & President of Blossom Innovations and Bob Rhatigan, CEO of Merz Americas.
The panel shares insights into how they help companies succeed through an infusion of capital and other resources. They identify and breakdown the key attributes of product and companies that increase the odds of securing funding.
The panel is moderated by AIS Co-Chair Josh Makower, General Partner of NEA Capital and Founder of ExploraMed, a medical device incubator.
Participants:
Craig Drill, President – Craig Drill Capital
Irina Erenburg, CEO & President – Blossom Innovations
Adele C. Oliva, Founding Partner – 1315 Capital
Bob Rhatigan, CEO – Merz Americas
Moderated By:
Josh Makower, MD, General Partner – NEA / Executive Chairman – ExploraMed
Podcast Guest
Josh Makower, MD
General Partner / Executive Chairman
NEA / ExploraMed
Josh has worked closely with NEA since his time as an EIR back in 1995 and joined full-time as a General Partner on NEA’s healthcare team leading their medtech/healthtech practice in 2015. Josh is also the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 8 companies over the past 20 years. Notable transactions from the ExploraMed portfolio include Acclarent, acquired by J&J in 2009; EndoMatrix, acquired by C.R. Bard in 1997; TransVascular, acquired by Medtronic in 2003; and Neotract, acquired by Teleflex in 2017. On-going ExploraMed/NEA ventures include Moximed, Willow and ExploraMed V.
In addition to his role at NEA, Josh serves on the faculty of the Stanford University Medical School as an Adjunct Professor of Medicine and is Co-Founder of Stanford’s Biodesign Innovation Program. Josh currently serves on the board of directors for DOTS Technology Corp., Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, SetPoint, Willow and Coravin. Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor’s degree in Mechanical Engineering from MIT.